The HB autoantigen, a 10-kDa DNA-binding protein recognized by autoantibodies only when bound to DNA, was identified by two-dimensional electrophoresis. Silver-stained protein spots corresponding to the antigen were excised from two-dimensional electrophoresis gels, digested with trypsin, and analyzed by matrix-assisted laser desorption/ionization-reflectron time of flight and nano-electrospray ionization-ion trap/mass spectrometry. Data base search identified the HB antigen as the barrier-to-autointegration factor, a cellular protein implicated in the cellular cycle that blocks autointegration and promotes intermolecular integration of retrovirus such as the Moloney murine leukemia and the human immunodeficiency type 1 virus. The physicochemical characteristics described for these proteins, their ability to bind double-stranded DNA but not single-stranded DNA, and their nuclear localization confirm that HB and barrier-to-autointegration factor are the same protein.
The presence of autoantibodies against nuclear structures is a characteristic feature of many autoimmune diseases. Although these autoantibodies have been correlated with disease activity, why they are produced and what role they play in pathologic processes remain unknown. Identification of autoantigens recognized by antinuclear antibodies is important for diagnosis and prognosis as well as for understanding the molecular and functional factors implicated in autoimmune diseases (1) .
There are many DNA-binding proteins among the nuclear structures recognized by autoantibodies (2) (3) (4) (5) (6) (7) . These proteins constitute a special kind of autoantigens as they can be found free or bound to DNA. The response in autoimmune processes is thought to be directed to DNA-protein complexes, and this hypothesis is important to understand the molecular etiopathology of autoimmune diseases. DNA-binding proteins could suffer conformational changes because of their interaction with DNA. Autoantibodies directed against the epitopes affected by these conformational changes could allow us to discriminate whether the autoimmune response is directed against the DNA-protein complex or directed against the free protein (2, 8 -10) . Nevertheless, this analysis is complicated by the presence of epitopes whose conformation is not affected by DNA binding. We have described previously the HB autoantigen, a DNA-binding protein recognized by autoantibodies only when bound to DNA, as a paradigm of an autoimmune response restricted to the protein-DNA complex (11) . The specificity of this response has been maintained for several years without any spreading to epitopes present in the free protein. In this paper, using a proteomic approach, we identified the HB autoantigen as the barrier-to-autointegration factor (BAF).
EXPERIMENTAL PROCEDURES
Sera-Four human sera with antibodies to HB antigen were used in this study. These sera were selected after nylon-DNA Western blot screening of 80 systemic lupus erythematosus (SLE) and 100 rheumatoid arthritis (RA) sera that contained antinuclear antibodies. 50 normal human sera (NHS) were also used as controls.
Preparation of Liver Nuclear Extract-Nuclei from livers of two 6-month-old mice were obtained as described previously (12) . The nuclear fraction was washed 3 times with 250 mM sorbitol, 10 mM Tris, pH 7.4, and incubated with 6 ml of Lysis Solution (8 M urea, 4% Triton X-100, 40 mM Tris, 5 mM DTT, 1ϫ protease inhibitor mixture). The mixture was sonicated 3 times with a Braun 2000 sonicator for 45 s each time at 60 watts and then centrifuged at 7,800 ϫ g and 4°C for 10 min, and the supernatant (Nuclear Sample) was stored frozen at Ϫ80°C.
One-dimensional Electrophoresis-Nuclear sample in LDS Sample Buffer (Invitrogen) supplemented with 20 mM 1,4-dithiothreitol (DTT) was warmed at 70°C for 10 min and applied to a pre-cast BisTris 12% gel (Invitrogen).
Two-dimensional Electrophoresis-Nuclear sample was processed using "Two-dimensional Clean Up Kit" (APBiotech, Uppsala, Sweden) as described by the manufacturer. One hundred l/strip of Nuclear Sample were mixed with 125 l/strip of Rehydration Buffer (8 M urea, 2% Triton X-100, 2% bromphenol blue, 3-10 IPG Buffer, 6 mM DTT) and applied overnight to 3-10NL IPG Strips (APBiotech). Isoelectric focusing was carried out at 3500 V and 2 mA for 9 h in a Multiphor II device (APBiotech). Strips were incubated with LDS Sample Buffer (Invitrogen) containing 20 mM DTT for 15 min. The equilibrated strips were loaded in a pre-cast 12% BisTris gel (Invitrogen) and run as described in one-dimensional electrophoresis. A MS-modified silver staining method was used as described in the literature (13) .
Western Blot-Gels were washed for 1 h with 25 mM Tris, 50 mM glycine and then transferred using Trans-Blot Cell (Bio-Rad) overnight at 80 mA to polyvinylidene difluoride (Millipore, Bedford, MA) or nylon membranes (Bio-Rad), previously incubated for 5 h with DNA (1 absorbance unit at 260 nm). Membranes were blocked with 5% non-fat dry milk in PBS (8 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 , 150 mM NaCl, pH 7.4). Sera from patients or NHS were diluted 1:100 in PBS, 3% non-fat dry * This work was supported by a grant from the Comissionat per a Universitats i Recerca (III Pla de Recerca de Catalunya, Exp. 2001SGR 00397) and by CICYT Grant SAF2000-0131-C01-02. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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Immunofluorescence-Commercially available Hep2 cells (INOVA Diagnostics, San Diego) were used to visualize the immunofluorescence pattern of the selected sera. Cells were first incubated with sera diluted 1:100 in PBS, washed, and incubated with fluorescence-labeled antihuman Ig (Dako).
Mass Spectrometry-Protein spot was excised with a scalpel. Prior to in-gel digestion, proteins were reduced with 10 mM DTT and alkylated with 55 mM iodoacetamide. Enzymatic digestion was performed with trypsin (Promega, Madison, WI) following conventional procedures as described (14, 15) . Digested samples were evaporated to dryness, redissolved in methanol/water (1:2 v/v), 1% acetic acid, and directly analyzed by MALDI-reTOF MS. Samples submitted to nESI-IT MS/MS analysis were de-salted using C18 ZipTips as indicated by the manufacturer.
The MALDI-reTOF MS analysis of the samples was performed using a Voyager DE-PRO MALDI-reTOF mass spectrometer (Applied Biosystems, Foster City, CA). The instrument was run in reflectron mode with an average resolution of 12,000 full-width half-maximum at m/z 1500. A 5 mg/ml ␣-cyano-4-hydroxycinnamic solution was used as MALDI matrix. Spectra were externally calibrated using a standard peptide mixture (angiotensin II, substance P, bombesin, and adrenocorticotropic hormone). Samples and calibration mixtures were spotted in alternate lines of a 10 ϫ 20 sample positions MALDI plate. Each sample was externally calibrated with the standard in the corresponding top left position in the plate. When the ions corresponding to known trypsin autolytic peptides (m/z 842.5100 and 2111.1046) were detected, a second automatic internal calibration of the spectra was performed using these ions as reference.
Nanospray MS/MS experiments were performed on a Finnigan LCQ ion trap mass spectrometer (ThermoQuest, Finnigan MAT, San Jose, CA) equipped with a nanospray interface (Protana, Odense, Denmark). The spray voltage applied was 0.85 kV, and the capillary temperature was 120°C. For MS/MS experiments, the isolation window was 3 mass units wide, and the relative collision energy was 20 -45%, depending on the charge of the precursor ion.
Data Base Search-The Protein Prospector software version 4.0.1 (University of California San Francisco, Mass Spectrometry Facility) was used to identify proteins from the peptide mass fingerprinting and peptide fragment-ion data obtained from MALDI-reTOF MS and nESI-IT MS/MS analyses, respectively. Swiss-Prot (European Bioinformatics Institute, Heidelberg, Germany) and GenBank TM (National Center for Biotechnology Information) data bases were used for the search.
RESULTS

Screening of Anti-HB Autoantibodies by One-dimensional
Electrophoresis and Western Blot-Antinuclear positive sera from 100 patients with RA, 80 patients with SLE, and 50 NHS were analyzed by WB to detect the presence of antibodies against the HB autoantigen. Fig. 1 shows the 4 sera in which we found the anti-HB specificity. One corresponds to a patient with RA as described previously (11) , and the other three sera correspond to patients with SLE. All sera recognized a 10-kDa protein only in the strips previously incubated with DNA. Reactivity of one of the SLE sera (Fig. 1, strip 5) , which shows the lower binding for the 10-kDa band in one-dimensional experiments, was further confirmed by two-dimensional electrophoresis experiments (data not shown).
Immunofluorescence Pattern of HB Serum-The immunofluorescence pattern of HB serum is shown in Fig. 2 . Serum recognizes a nuclear antigen that gives a weak homogeneous pattern with a strong peripheral staining.
Two-dimensional Electrophoresis-Liver nuclear extracts were fractionated by two-dimensional electrophoresis as described under "Experimental Procedures." Two gels were run in parallel; one was silver-stained, and the other was transferred to a DNA-Nylon membrane and antigen detected using the HB serum. Fig. 3 shows that patient's serum recognized one protein (Fig. 3B ) that could be clearly assigned to one of the silver-stained spots (Fig. 3A) . This spot was excised and processed for mass spectrometry analysis.
Protein Identification-No matches were obtained from the MALDI-reTOF spectrum, probably because the number of generated peptides from such a small protein was not high enough to produce a clear match. However, the mass signals detected by MALDI-reTOF MS could be used for the blind selection of nESI precursor ions submitted to MS/MS fragmentation as shown in Fig. 4 for the doubly charged positive ion at m/z 675.4. This peptide could be partially sequenced to give the VVLGQ-FLVLK peptide tag. This tag was identified with the AYVVL-GQFLVLK tryptic peptide of the BAF protein by data base search. Two other peptide signals were fragmented both leading to the identification of the same BAF protein (Fig. 5) . The three identified peptides account for 48.3% of the mouse BAF sequence annotated in the Swiss Protein Database. Theoretical molecular mass and isoelectric points of BAF (10 kDa; pI 5.8) are coincident with those calculated from the two-dimensional electrophoresis gel (Fig. 3) . DISCUSSION In the present study the HB autoantigen was identified as the protein BAF by means of two-dimensional electrophoresis FIG. 1. Sera screening using Nylon-DNA WB and polyvinylidene difluoride WB. Normal human serum (strips 1 and 2), HB serum (strips 3 and 4), and sera from three SLE patients (patient 1, strips 5 and 6; patient 2, strips 7 and 8; and patient 3, strips 9 and 10) were incubated on DNA-Nylon membrane (strips 1, 3, 5, 7, and 9) or on polyvinylidene difluoride membrane (strips 2, 4, 6, 8, and 10) . HB antigen was recognized on strips 3, 5, 7, and 9. Serum corresponding to strip 5 shows lower reactivity than the other sera and was confirmed in several independent experiments. and nESI-IT MS/MS. The similarity in the characteristics described previously for the HB antigen (11) and the BAF protein further support this conclusion. Both proteins (a) are able to bind double strand DNA, without specific sequence requirements (16, 17) , but not single strand DNA or RNA (18); (b) have a perinuclear, nuclear, and chromosomal localization (19) ; (c) undergo conformational changes after DNA binding (20) ; and (d) are dimers in solution (21) .
The autoantibody specificity has been found in another three sera from lupus erythematosus patients. Combination of onedimensional electrophoresis and WB on DNA-Nylon paper was chosen as the screening technique. The homogeneous nuclear and perinuclear staining observed with the HB serum by immunofluorescence is not specific for the HB antigen; moreover, other antinuclear specificities present in other sera encumber the identification of the HB staining. Two of the SLE sera with HB specificity had also Ro/La and ribonucleoprotein specificities, respectively. The third sera also presented other additional specificities that could not be identified.
The reactivity of serum from patient in strip 5 ( Fig. 1) , showing the lowest reactivity against BAF protein, was further confirmed in several independent one-and two-dimensional electrophoresis experiments (data not shown). Recognition strength depends on autoantibody level and affinity for the spectrum of epitopes that each serum is able to recognize. We do not yet know whether the antibodies in this serum bind epitopes also recognized by the other sera but with a lower level or affinity, or whether they are directed against other epitopes, which are not well recognized in the experimental conditions used.
The four sera recognized BAF bound to DNA, whereas none of the RA sera or the 80 SLE sera tested recognized the 10-kDa band on the strip without DNA. Therefore, when an autoimmune response occurs against BAF, this is directed against the complex DNA-BAF and not against free BAF. This event could also occur in the case of other DNA-binding proteins recognized by autoantibodies. In fact, autoantibodies against conformational epitopes present exclusively in proteins bound to DNA have also been described by other authors (8 -10) . Nevertheless, in these cases, polyclonal autoimmune responses are also directed against epitopes present both in free and bound protein; therefore, the absolute restriction of response to DNAprotein complex could not be demonstrated. In the present case, the restriction of the response to DNA complex is clearly demonstrated, making this autoantigen unique for these studies. The reason for this could be because of the small size of this antigen (89 amino acids) and the induction of conformational changes after interaction with DNA. The crystal structure of the BAF dimer has been solved (16) . but the structure of the BAF-DNA complex has not. Nevertheless, evidence for conformational changes in BAF have been described (20) . Conformational changes have also been reported for other DNA-binding proteins (22, 23) and for the DNA-binding domain of some transcription factors (24, 25) . Because of the small size of BAF, conformational changes induced by DNA binding would probably affect almost the whole protein, in a similar way to the DNA-binding domain of transcription factors described above. Although we cannot formally discard the possibility that autoantibodies recognize changes in DNA conformation induced by BAF or epitopes constituted by protein and DNA residues, we favor the hypothesis that autoantibodies recognize the protein in the BAF-DNA complex. This is because DNase treatments of already formed immunocomplexes do not disturb the interaction BAF-antibody in immunoprecipitation studies (data not shown).
BAF interacts with various components of the inner nuclear membrane, including lamina-associated polypeptide 2 and emerin (19, 26, 27) . It also plays a key role in integration of retroviral cDNA for its ability in binding to large nucleoprotein complexes, named preintegration complexes (PICs), derived from cores of infecting virions (16, 18, 28 -30) . Retroviruses have repeatedly been suggested as possible agents that trigger animal and human autoimmune diseases by their ability to alter cell responses or to break tolerance to some autoantigens. Tolerance to self-proteins can be broken by molecular mimicry (31) but also by generating novel structures such as PICs, where host proteins like BAF are complexed with viral proteins and cDNA. Therefore, the immune response will be initially directed against viral proteins in PICs and spread to BAF present in these particles. The same process could occur with Ku-80, another PICs component (28) that is recognized by autoantibodies in myositis patients.
Because of the significant changes that seem to be induced in the BAF-DNA complex, studies are ongoing in our laboratory to analyze whether sera from patients are able to discriminate the BAF-DNA complex in PICs from the BAF-host DNA complex. If autoantibodies were able to perform this discrimination, they would be a powerful tool not only to trace structures responsible for breaking the tolerance to the BAF-DNA complex but also to give important clues for designing therapeutic drugs able to block the integration of human immunodeficiency virus type and other retrovirus in host DNA without interfering with their cellular functions.
